Salute e Benessere

Postherpetic Neuralgia Market to Accelerate Significantly at a CAGR of 14% by…

Key Takeaways from the Postherpetic Neuralgia Market Report Key Takeaways from the Postherpetic Neuralgia Market Report Discover which therapies are expected to grab the major postherpetic neuralgia market share @ Postherpetic Neuralgia Market Report Postherpetic Neuralgia Overview Postherpetic neuralgia is a frequent complication of shingles, which arises from the reactivation of the varicella-zoster virus (VZV) that remains dormant in the body after an initial varicella infection...
PR Newswire
10/06/2024

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of…

Ipsen's Iqirvo ®(elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC)First-ever drug developed in-house by GENFIT to achieve U.S. FDA's approvalGENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S., as well as tiered double-digit royalties of up to 20% Lille (France), Cambridge (Massachusetts, United States), Zurich...
Nasdaq GlobeNewswire
10/06/2024

Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR…

Iqirvo ®(elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial dataPrimary biliary cholangitis impacts approximately 100,000 people in the US and is growing in global prevalence. If inadequately treated, it can cause liver failureU.S...
Nasdaq GlobeNewswire
10/06/2024

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661…

LRP-661's data highlights its superior safety, efficacy, bioavailability, and PK in multiple species. Furthermore, LRP-661's oral formulation ability compared to cannabidiol, marks a significant advancement in the field of epilepsy treatment. Notably, the compound demonstrates exceptional efficacy in PTZ fully kindled mice, Maximal Electroshock Seizure (MES), MES Threshold, and pentylenetetrazol (PTZ)–induced seizure data.When compared against the currently available oral solution of...
Nasdaq GlobeNewswire
10/06/2024

Medical Virtual Assistant Market Size to Grow USD 2668.4 Million by 2029 at a…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19Y16064/Global_Medical_Virtual_Assistant_Market Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19Y16064/Global_Medical_Virtual_Assistant_Market Major Factors driving the growth of Medical Virtual Assistant market: The growing desire for individualized patient experiences, affordable healthcare solutions, and the expanding use of AI and machine learning technologies in the healthcare...
PR Newswire
10/06/2024

Partnership of Spineway with the SFCR for June 24 congress

Press release Ecully, June 10, 2024 – 6 p.m. SPINEWAY partners with the Société Française de Chirurgie du Rachis (SFCR) Congress in Montpellier, France The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, announces that it will be a partner of the Société Française de Chirurgie du Rachis (SFCR) Congress, one of the most important spine surgery events in France. The new edition will be held from June 13 to 15, 2024 at the Corum...
Nasdaq GlobeNewswire
10/06/2024

Hormone Replacement Therapy Market Size to Grow USD 18280 Million by 2030 at a…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-19G13044/Global_Hormone_Replacement_Therapy_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-19G13044/Global_Hormone_Replacement_Therapy_Market Major Factors Driving the Growth of Hormone Replacement Therapy Market: The need for effective treatment methods, such as hormone replacement therapy (HRT), has increased due to the rising prevalence of menopausal symptoms among aging...
PR Newswire
10/06/2024

Drug Discovery Informatics Market Size to Grow USD 1 Million by 2030 at a CAGR…

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-14V4103/Global_Drug_Discovery_Informatics_Market Get Free Sample:https://reports.valuates.com/request/sample/QYRE-Auto-14V4103/Global_Drug_Discovery_Informatics_Market Major Factors Driving the Growth of Drug Discovery Informatics Market: The desire for tailored treatment, growing investment in pharmaceutical R&D, and technological improvements are the main factors driving the growth of the Drug Discovery...
PR Newswire
10/06/2024

Chlorella Market to Reach $639.7 Million by 2031 - Exclusive Report by…

Chlorella is a genus of green algae that have a spherical shape. The cultivation of chlorella involves relatively limited resources. Some of the main applications of the genus Chlorella are in biofuels (biodiesel, biomethane, and biohydrogen), cosmetics (skincare), supplementary foods (polyunsaturated fatty acids), pigments (carotenoids and chlorophyll), and waste-water treatments (reduction of chemical oxygen demand and bioremediation). Chlorella is a genus of green algae that have a spherical…
PR Newswire
10/06/2024

Medical Laser Market to Be Worth $17.3 Billion by 2031 - Exclusive Report by…

Medical lasers are devices that use precisely focused light sources for treating or removing tissues. Since lasers can focus accurately on tiny areas, they are used for precise surgical works or for cutting through tissue in place of a scalpel. Lasers are commonly employed in many medical disciplines, including dermatology, dentistry, cardiology, neurosurgery, and eye surgery, because of their ability to deliver high-precision treatments while remaining minimally invasive. Laser-based therapies…
PR Newswire
10/06/2024

Dural Adhesive Agent for the Surgical Market Worth USD 263.2 Million by 2031 -…

Dural adhesive agents for the surgical market are experiencing significant growth, propelled by the increasing prevalence of neurological disorders, the growing aging population, and technological advancements in neurosurgical techniques. The dural adhesive agent for the surgical market is focused on products used to seal and repair the dura mater. The increasing occurrence of neurological disorders and the rising number of neurosurgeries globally drive the market. Dural adhesive agents for…
PR Newswire
10/06/2024

Exosome Diagnostics and Therapeutics Market Surges, Anticipated to Hit USD 6,848…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198025144 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198025144 Browse in-depth TOC on "Exosome Diagnostics and Therapeutics Market" 335 - Tables45 - Figures250 - Pages Exosome Diagnostics Segment Leads Market Share in 2023 In 2023, the exosome diagnostics segment emerged as the frontrunner in market share, underscoring its pivotal role in driving...
PR Newswire
10/06/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from June 3, 2024, to June 7, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
10/06/2024

Cell & Gene Therapy Supply Chain Software Market Expected to Grow at a 13.9%…

Enhanced therapies, including cell and gene therapy products, have reformed healthcare practices. The prevalence of such therapeutic options has led to an uprise shift in modern medicine's development, production, and consumption. Moreover, such therapies have established healthcare providers to treat several rare clinical conditions. Enhanced therapies, including cell and gene therapy products, have reformed healthcare practices. The prevalence of such therapeutic options has led to an…
PR Newswire
10/06/2024

Cell and Gene Therapy CRO Market Review Report 2024-2031 | Latest by InsightAce…

Gene therapies are a type of medicine that has the potential to treat many different ailments. Whereas conventional medicine focuses on alleviating symptoms, their strategy is to deal with the sources of ailments. Also, they have the potential to help with a wide variety of ailments that have not responded to other treatments, including those involving the eyes, the nervous system, and cancer. One approach to gene therapy that makes use of viral vectors is the delivery of therapeutic genes to…
PR Newswire
10/06/2024

Smartee Successfully Hosts GS Mandibular Repositioning Conference in Spain

Professor Shen highlighted the challenges of severe malocclusions with skeletal components in the current orthodontic world. He emphasized that severe Class II jaw discrepancies, often caused by maxillary overgrowth and mandibular retrusion, result in a prognathic facial profile and malocclusion characterized by increased overjet, overbite, and a deep curve of Spee. One crucial treatment modality for this condition is the forward repositioning of the mandible, leading to regional adaptive…
PR Newswire
10/06/2024

2024 American Oncology Annual Meeting Concludes in Chicago, CANCER CASES SURGE…

Cancer Driver Interception: The New Frontier of Prevention Cancer Driver Interception: The New Frontier of Prevention Developed by a spin-off of the University of Rome Tor Vergata, the HELIXAFE protocol, using the Cancer Driver Inteception methodology, represents an active prevention strategy against conditions that can lead to cancer development. ProfessorAdriana Albini ,Head of the Cancer Prevention Working Group at AACR(American Association for Cancer Research), and Board...
PR Newswire
10/06/2024

ZINZINO AB (PUBL): ANNUAL REPORT ENGLISH 2023

For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com For more information:Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700,zinzino.com Pictures for publication free of charge: marketing@zinzino.com Certified Adviser: Carnegie Investment Bank AB (publ) This information was brought to you by Cisionhttp://news.cision.com. https://news.cision.com/zinzino/r/zinzino-ab--publ--annual-report-english-2023,c3997891 The following...
PR Newswire
10/06/2024

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with…

ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA “The real-world evidence used in our clinical research continues to demonstrate the effectiveness of PAP therapy for treating OSA,” said Carlos M. Nunez, MD, ResMed's Chief Medical Officer. “The studies presented at SLEEP 2024 expand our understanding of patients with sleep disorders by examining...
Nasdaq GlobeNewswire
10/06/2024

Octapharma's continuing dedication to improving the lives of people with rare…

Bleeding disorders, such as haemophilia A and von Willebrand disease (VWD), carry the risk of recurrent and prolonged bleeds, which can not only be life-threatening but also take a heavy toll on patients' quality of life and mental health. Bleeding disorders, such as haemophilia A and von Willebrand disease (VWD), carry the risk of recurrent and prolonged bleeds, which can not only be life-threatening but also take a heavy toll on patients' quality of life and mental health. The...
PR Newswire
10/06/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 10 June 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the…
Nasdaq GlobeNewswire
10/06/2024

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA…

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody ®sonelokimab in Psoriatic Arthritis Builds upon the positive regulatory feedback received from FDA and EMA on Phase 3 VELA program for sonelokimab in hidradenitis suppurativa (HS), which has started recruitmentClarified path for PsA Phase 3 program with study design, patient population and endpoints agreed – program is called IZAR and two...
Nasdaq GlobeNewswire
10/06/2024

Eve Communications, Inc. to Showcase at What's Next Longevity Venture Summit…

"Loneliness and dementia are the twin epidemics of our time," says Ivan Wicksteed, Founder & CEO of Eve Communications. He refers to the Surgeon General's recent report, which equates loneliness to smoking 15 cigarettes per day. "Loneliness and dementia are the twin epidemics of our time," saysIvan Wicksteed, Founder & CEO of Eve Communications. He refers to the Surgeon General's recent report, which equates loneliness to smoking 15 cigarettes per day. Eve is…
PR Newswire
10/06/2024

Endo Launches New Dupuytren's Contracture Campaign: Reminders

"I've seen patients who've coped with Dupuytren's contracture for longer than necessary because a healthcare provider presented two paths: living with the condition or undergoing surgery," said Dr. Damon Adamany, an orthopedic hand surgeon at The CORE Institute. "I believe that if patients aren't comfortable with the options presented, they should get a second opinion." "I've seen patients who've coped with Dupuytren's contracture for longer than necessary because a…
PR Newswire
10/06/2024
Altri  Comunicati